Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Hepatitis C still increasing in German gay men with HIV, reinfection common

A survey from the main HIV clinic in Hamburg, Germany, presented at the Tenth Congress on Drug Therapy in HIV Infection in Glasgow, has found that

Published
12 November 2010
By
Gus Cairns
Early analysis finds good outcomes with once-daily dosing of HCV protease inhibitor TMC435

Tibotec's investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, TMC435, produced good viral suppression in previously untreated genotype 1 patients when taken once-daily in combination with pegylated interferon plus ribavirin for 12 or 24 weeks, according to interim results from the PILLAR study.

Published
08 November 2010
From
HIVandhepatitis.com
From podium to practice: Updates in HCV treatment

CCO official conference coverage of the 2010 Annual Meeting of the American Association for the Study of Liver Diseases.

Published
08 November 2010
From
Clinical Care Options (registration required)
Hepatitis C researcher arrested on insider trading charges

A prominent French doctor has been arrested on criminal fraud charges that accused him of tipping off a hedge fund manager about setbacks in a clinical drug trial that had not yet been made public, federal authorities said Tuesday.

Published
03 November 2010
From
New York Times
AASLD: Anti-HCV drug boosts response rates

Combining the direct anti-viral agent telaprevir with standard hepatitis C care can sharply improve response rates and shorten the treatment period, researchers reported.

Published
03 November 2010
From
MedPage Today
New tool developed to predict success of hepatitis C therapy in HIV/HCV-co-infected patients

Spanish investigators have developed a non-invasive diagnostic tool that can accurately predict which HIV-positive patients who are co-infected with hepatitis C virus will successfully respond to treatment

Published
02 November 2010
By
Michael Carter
AASLD: Successful HCV Tx cuts deaths post-transplant

After a liver transplant, successful treatment for hepatitis C significantly reduces the risk of death, researchers reported here.

Published
01 November 2010
From
MedPage Today
Gilead presents phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

Published
01 November 2010
From
The Medical News
Longer Hep C Treatment Improves Response in People Coinfected With HIV

People coinfected with both HIV and hepatitis C virus (HCV) who fail to respond rapidly to HCV treatment are more likely to achieve a cure for their HCV if they extend their treatment by at least six months. These data were presented at the American Association for the Study of Liver Diseases being held October 29 to November 2 in Boston.

Published
01 November 2010
From
AIDSMeds
Black patients fare well on Vertex hepatitis C drug

A closer look at data from a late stage trial of Vertex Pharmaceuticals Inc's eagerly anticipated hepatitis C drug telaprevir showed impressive cure rates for black patients and for patients with advanced liver disease.

Published
31 October 2010
From
Reuters

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.